189 related articles for article (PubMed ID: 28322590)
1. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
Penny WF; Hammond HK
Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
[TBL] [Abstract][Full Text] [Related]
2. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
[TBL] [Abstract][Full Text] [Related]
3. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.
Hammond HK; Penny WF; Traverse JH; Henry TD; Watkins MW; Yancy CW; Sweis RN; Adler ED; Patel AN; Murray DR; Ross RS; Bhargava V; Maisel A; Barnard DD; Lai NC; Dalton ND; Lee ML; Narayan SM; Blanchard DG; Gao MH
JAMA Cardiol; 2016 May; 1(2):163-71. PubMed ID: 27437887
[TBL] [Abstract][Full Text] [Related]
5. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
[TBL] [Abstract][Full Text] [Related]
7. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
Zhai Y; Luo Y; Wu P; Li D
J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
[TBL] [Abstract][Full Text] [Related]
8. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
Lyon AR; Babalis D; Morley-Smith AC; Hedger M; Suarez Barrientos A; Foldes G; Couch LS; Chowdhury RA; Tzortzis KN; Peters NS; Rog-Zielinska EA; Yang HY; Welch S; Bowles CT; Rahman Haley S; Bell AR; Rice A; Sasikaran T; Johnson NA; Falaschetti E; Parameshwar J; Lewis C; Tsui S; Simon A; Pepper J; Rudy JJ; Zsebo KM; Macleod KT; Terracciano CM; Hajjar RJ; Banner N; Harding SE
Gene Ther; 2020 Dec; 27(12):579-590. PubMed ID: 32669717
[TBL] [Abstract][Full Text] [Related]
10. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.
Jaski BE; Jessup ML; Mancini DM; Cappola TP; Pauly DF; Greenberg B; Borow K; Dittrich H; Zsebo KM; Hajjar RJ;
J Card Fail; 2009 Apr; 15(3):171-81. PubMed ID: 19327618
[TBL] [Abstract][Full Text] [Related]
11. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
[TBL] [Abstract][Full Text] [Related]
12. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for heart failure.
Greenberg B
J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
[TBL] [Abstract][Full Text] [Related]
14. [Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].
Hui HP; Li XY; Liu XH; Sun S; Lu XC; Liu T; Yang W
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):357-62. PubMed ID: 16776934
[TBL] [Abstract][Full Text] [Related]
15. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.
Tilemann L; Lee A; Ishikawa K; Aguero J; Rapti K; Santos-Gallego C; Kohlbrenner E; Fish KM; Kho C; Hajjar RJ
Sci Transl Med; 2013 Nov; 5(211):211ra159. PubMed ID: 24225946
[TBL] [Abstract][Full Text] [Related]
16. Improvement in cardiac function after sarcoplasmic reticulum Ca2+-ATPase gene transfer in a beagle heart failure model.
Mi YF; Li XY; Tang LJ; Lu XC; Fu ZQ; Ye WH
Chin Med J (Engl); 2009 Jun; 122(12):1423-8. PubMed ID: 19567165
[TBL] [Abstract][Full Text] [Related]
17. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
Kawase Y; Ly HQ; Prunier F; Lebeche D; Shi Y; Jin H; Hadri L; Yoneyama R; Hoshino K; Takewa Y; Sakata S; Peluso R; Zsebo K; Gwathmey JK; Tardif JC; Tanguay JF; Hajjar RJ
J Am Coll Cardiol; 2008 Mar; 51(11):1112-9. PubMed ID: 18342232
[TBL] [Abstract][Full Text] [Related]
18. [Gene therapy in heart failure: the unexpected results from the CUPID 2 trial].
Gigli M; Sinagra G; Mestroni L
G Ital Cardiol (Rome); 2017 Feb; 18(2):101-105. PubMed ID: 28398363
[TBL] [Abstract][Full Text] [Related]
19. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
Hajjar RJ; Zsebo K; Deckelbaum L; Thompson C; Rudy J; Yaroshinsky A; Ly H; Kawase Y; Wagner K; Borow K; Jaski B; London B; Greenberg B; Pauly DF; Patten R; Starling R; Mancini D; Jessup M
J Card Fail; 2008 Jun; 14(5):355-67. PubMed ID: 18514926
[TBL] [Abstract][Full Text] [Related]
20. [Overexpression of sarcoplasmic reticulum calcium ATPase induced hemodynamic and proteomic changes in a dog model of heart failure].
Fu ZQ; Li XY; Liu XH; Sun S; Liu T; Mi YF; Zhou SA; Ye WH; Wang QS
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar; 36(3):260-5. PubMed ID: 19099986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
